65 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding … compensation for one of the Company’s U.S. subsidiaries, Immunocore LLC, following an annual assessment, or periodically as required, of all available
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
president, drug assessment and development, at Chiron Corporation. Dr. Jallal has served on the board of directors of Elevance Health, Inc. (formerly Anthem … our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
. Jallal was vice president, drug assessment and development, at Chiron Corporation. Dr. Jallal has served on the board of directors of Elevance Health … risk assessment and management is undertaken. The audit committee also reviews and receives regular briefings concerning information security
10-K
2023 FY
EX-10.14
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
Salary (the “Target Bonus”). The Annual Bonus will be based upon the assessment of the Board of Directors (the “Board”) of Immunocore Holdings Plc … Market Value (as defined in the Plan) of 200% of your then-current Base Salary. The Annual Equity Award will be based upon the assessment of the Board
10-K
2023 FY
EX-10.13
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
Bonus will be based upon the assessment of the Board (or a committee thereof) of Executive’s performance and the Company’s attainment of targeted goals
10-K
EX-10.12
lnlspo
28 Feb 24
Annual report
7:33am
10-K
bxn w6v2sqj
28 Feb 24
Annual report
7:33am
8-K
EX-4.1
upbhi6
2 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
4:05pm
6-K
EX-99.2
hjlu f6u6d9cvvjw2mbx
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
xmwpegt4woxvq8d
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
hbiet4uhzn1m0 rpz4a
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
gegu03u6
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
ncipokg24 febijvjp
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
3rxxmllxg6so10yeozbb
10 May 23
Current report (foreign)
7:27am
6-K
y4vnfv 7f2
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
h3d1wwja1t3
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K/A
EX-99.1
ln2gozm nqkxx
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.4
icsh8 ph7kgd
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
fi6ofi9btckkyhl6fj
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.1
4xrgiyf 5728cdfclff
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am